Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Assets (2023 - 2025)

Telix Pharmaceuticals has reported Assets over the past 3 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly Assets rose 17.38% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $991.7 million through Dec 2024, up 275.25% year-over-year, with the annual reading at $1.2 billion for FY2025, 17.38% up from the prior year.
  • Assets was $1.2 billion for Q4 2025 at Telix Pharmaceuticals, up from $991.7 million in the prior quarter.
  • Over five years, Assets peaked at $1.2 billion in Q4 2025 and troughed at $264.3 million in Q4 2023.
  • The 3-year median for Assets is $991.7 million (2024), against an average of $806.6 million.
  • Year-over-year, Assets surged 275.25% in 2024 and then increased 17.38% in 2025.
  • A 3-year view of Assets shows it stood at $264.3 million in 2023, then surged by 275.25% to $991.7 million in 2024, then grew by 17.38% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for TLX's Assets are $1.2 billion (Q4 2025), $991.7 million (Q4 2024), and $264.3 million (Q4 2023).